The FDA this week issued its first warning letter under the Drug Supply Chain Security Act to McKesson Corp., of San Francisco, for violations involving illegitimate drugs in its supply chain. Some of the violations stemmed from a tampering incident in which a customer notified McKesson that three of its pharmacy locations in Michigan had received bottles that were supposed to contain opioid pills.